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PROTECTION AGAINST ISCHEMIA AND 
REPERFUSION INJURY 
This application claims the bene?t of US. application 
Ser. No. 60/232,093, ?led Sep. 12, 2000. 
FIELD OF THE INVENTION 
The invention relates to compounds protective against 
ischemia and reperfusion injury, particularly in the 
myocardium, and their use. 
BACKGROUND 
Tissues deprived of blood and oxygen undergo ischemic 
necrosis or infarction With possible irreversible organ dam 
age. In some circumstances, hoWever, such as during cardiac 
surgery, it is desirable to interrupt the normal myocardial 
contractions (cardioplegia) and actually induce ischemia. 
Such elective or obligatory ischemia occurs in the presence 
of safeguards such as cardioplegia-induced cardiac arrest 
and hypothermia. While these safeguards provide consider 
able myocardial protection, alteration of myocardial ener 
getics (stunning) and poor postoperative ventricular function 
still remain signi?cant problems. 
Once the How of blood and oxygen is restored to the organ 
or tissue (reperfusion), the organ does not immediately 
return to the normal preischemic state. Reperfused postis 
chemic non-necrotic myocardium is poorly contractile and 
has reduced concentrations of high energy nucleotides, 
depressed subcellular organelle function and membrane 
damage that resolves only sloWly. Although reperfusion 
restores oxygen and reverses ischemia, repletion of high 
energy nucleotides such as adenosine triphosphate (ATP) 
and reversal of ischemic membrane damage is sloW, and 
contractile function may be profoundly depressed for a long 
period. Just minutes of ischemia causes loss of myocardial 
systolic Wall thickening for hours. Longer periods of revers 
ible ischemia may depress contractility for days. Studies 
con?rm that, despite restoration of myocardial How and a 
quick recovery of myocardial oxygen consumption (MVO2) 
folloWing ischemia, there is only very sloW recovery of 
myocardial contractile function. The problems are exacer 
bated in high risk patients, such as those With poor preop 
erative ventricular function, recent myocardial infarction or 
left ventricular hypertrophy. These same problems also 
occur during organ storage for cardiac transplant, under 
Which there are time constraints due to the limits of myo 
cardial preservation. 
Postischemic dysfunction may be due to a variety of 
factors. Oxygen free radicals may play a role, as generation 
of free radicals in stunned myocardium has been demon 
strated and free radical scavengers have been shoWn to 
attenuate contractile dysfunction. Impaired intracellular cal 
cium handling and calcium overload during early reperfu 
sion may contribute to postischemic dysfunction; While 
calcium infusions enhance contractility in both normal and 
postischemic myocardium, ischemia as short as a feW min 
utes produces an impairment in sarcoplasmic reticulum 
calcium transport and a shift of the calcium ATPase activity. 
Postischemic myocardium is also associated With reduced 
concentrations of myocardial high-energy phosphates and 
adenine nucleotides, as obligatory reduction in myocardial 
ATP content during ischemia occurs as myocytes utiliZe ATP 
for maintenance of cellular integrity. Since ATP is essential 
for myocardial contraction and relaxation, ATP depletion 
may have detrimental effects upon postischemic myocardial 
functional recovery. 
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The high volume of cardiac-related surgeries, both elec 
tive and emergency procedures and including cardiac 
transplants, lead to the above-described problems. Thus, 
methods and agents to provide protection against myocardial 
ischemia and to avoid post ischemic dysfunction are needed. 
SUMMARY OF THE INVENTION 
The invention is directed to agents and a method of using 
the agents to reduce the injury associated With ischemia and 
reperfusion of organs such as the heart. The compounds are 
Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 SEQ ID NO:1, 
hereinafter referred to as Deltorphin A, and Tyr-D-Ala-Phe 
Gly-Tyr-Pro-Ser-Gly-Glu-Ala-Lys-Lys-Ile SEQ ID NO:2, 
hereinafter referred to as Dermorphin H. Administration of 
Deltorphin A SEQ ID NO:1 and Dermorphin H SEQ ID 
NO:2, particularly prior to an ischemic event, reduces tissue 
necrosis and preserves organ function. 
In one embodiment, a method of protecting against 
ischemia and reperfusion injury in a mammal is disclosed. 
An effective concentration of DeltorphinASEQ ID NO:1 or 
Dermorphin H SEQ ID NO:2 is administered to the mammal 
in a pharmaceutically acceptable formulation prior to the 
onset of ischemia, for example, 24 hours prior to ischemia. 
In other embodiments, Deltorphin A SEQ ID NO:1 or 
Dermorphin H SEQ ID NO:2 is administered substantially 
concurrently With the onset of ischemia, during an ischemic 
episode, or post-ischemia. The formulation may be admin 
istered parenterally at a concentration in the range of about 
1—20 mg/kg of body Weight. 
The invention is also directed to a method to prevent 
damage to an isolated organ, for example, a heart for 
transplant. The isolated organ is exposed to a preservative 
solution containing an effective amount of Deltorphin A 
SEQ ID NO:1 or Dermorphin H SEQ ID NO:2. The con 
centration of Deltorphin A SEQ ID NO:1 or Dermorphin H 
SEQ ID NO:2 in the preservative solution for a heart is about 
100 pM. 
The invention is additionally directed to a method for 
reducing effects of an ischemic episode in a mammal by 
administering an effective concentration of Deltorphin A 
SEQ ID NO:1 or Dermorphin H SEQ ID NO:2 in a phar 
maceutically acceptable carrier. Administration is prior to or 
substantially concurrently With the onset of ischemia, or one 
hour post cerebral ischemia. 
The invention is further directed to a composition that 
protects a mammalian organ from injury. The composition 
contains Deltorphin ASEQ ID NO:1 or Dermorphin H SEQ 
ID NO:2, in either a naturally occurring form or a synthe 
siZed form. 
The invention is also directed to an organ preservative 
solution that contains Deltorphin A SEQ ID NO:1 or Der 
morphin H SEQ ID NO:2 at a concentration effective to 
protect the organ, such as a heart, from ischemic injury. 
These and other advantages of the invention Will be 
apparent in light of the folloWing draWings and detailed 
description. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a histogram shoWing myocardial infarction siZe 
in control and treated animals. 
FIG. 2 is a histogram shoWing post-ischemic release of 
troponin I in control and treated animals. 
FIG. 3 is a graph shoWing end diastolic pressure in the left 
ventricle of control and treated animals. 
FIG. 4 is a graph shoWing functional recovery in control 
and treated animals. 
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FIG. 5 is a histogram showing ventricular functional 
recovery in control and treated animals. 
DETAILED DESCRIPTION 
The invention is directed to compounds that have a 
salutary effect on cardiac function following ischemia, and 
methods of using the compounds. The compounds may be 
administered directly to an individual, and are particularly 
effective When administered 24 h prior to the onset of 
ischemia. This may occur, for example, prior to scheduled 
cardiac surgery. The compounds may also be included in a 
preservative solution for an isolated organ, such as a heart or 
liver being maintained viable for transplant. 
One of the compounds is a heptapeptide having the 
sequence Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 SEQ ID 
NO:1, hereinafter referred to as deltorphin A. Another of the 
compounds is a thirteen amino acid sequence Tyr-D-Ala 
Phe-Gly-Tyr-Pro-Ser-Gly-Glu-Ala-Lys-Lys-Ile SEQ ID 
NO:2. The peptides may be produced by a number of 
methods, such as using an automated peptide synthesiZer, 
through recombinant molecular techniques, or isolated from 
a naturally occurring source, as is knoWn to one skilled in the 
art. Deltorphin A SEQ ID NO:1 has a molecular Weight of 
955.1 daltons, and Dermorphin H SEQ ID NO:2 has a 
molecular Weight of about 1430.64 daltons. Both Deltorphin 
A SEQ ID NO:1 and Dermorphin H SEQ ID NO:2 are 
insoluble in Water or saline, but may be solubiliZed by 
adding 100 pM of a solution comprised of ethanol, propy 
lene glycol, and 1 N NaOH in a 1:111 ratio, With sterile 
physiological saline then used to obtain the appropriate 
concentration. The initial alkaline pH is adjusted to 7.4 With 
1 N HCl. 
Deltorphin A SEQ ID NO:1 and Dermorphin H SEQ ID 
NO:2 that have been solubiliZed may be administered by 
parenteral means, for example, intravenous injection. In one 
embodiment, administration of Deltorphin A SEQ ID NO:1 
is at the time of induced ischemia, but may also be added 
during or even after an ischemic event. For administration 
into a mammal, a dose of about 1—20 milligrams per 
kilogram (mg/kg) is useful. For administration into a tissue 
or organ preservation solution, a concentration of about 100 
pM is useful. 
Deltorphin A SEQ ID NO:1 and Dermorphin H SEQ ID 
NO:2 may be administered directly into a mammal, either 
alone or in combination With other substances. Alternatively, 
it may be added as a component of a solution used to 
maintain the viability of isolated organs, such as an additive 
to cardioplegia and other organ preservation solutions. In 
one embodiment, Deltorphin A SEQ ID NO:1 and/or Der 
morphin H SEQ ID NO:2 is coadministered as an adjuvant 
With other compounds or strategies that are designed to 
protect organs from ischemia. As an example, Deltorphin A 
SEQ ID NO:1 and/or Dermorphin H SEQ ID NO:2 may be 
administered With agents that affect nitric oxide (NO) 
synthase, such as arginine hydrochloride. Arginine hydro 
chloride is knoWn to prevent the decline in cardiac function 
folloWing an ischemic episode. 
The folloWing description demonstrates use and ef?cacy 
of Deltorphin A SEQ ID NO:1 and Dermorphin H SEQ ID 
NO:2 in a variety of systems. 
Perfused Heart 
Deltorphin A SEQ ID NO:1 or Dermorphin H SEQ ID 
NO:2, at a dose of 2 mg/kg and solubiliZed as described 
above, Was administered by tail vein injection into rats 
Weighing betWeen about 350—400 g (number of animals 
(n)=6). Control rats (n=6) Were injected in the same manner 
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With an equal volume of 0.9% NaCl. After 24 h, the hearts 
from both treated and control animals Were excised and 
perfused in a modi?ed Langendorff perfusion apparatus at 
37° C. using oxygenated Krebs-Henseleit buffer as the 
perfusate, as knoWn to one skilled in the art. Coronary 
perfusion pressure Was maintained at 700 mm Hg by regu 
lating coronary ?oW. All hearts Were paced at 5.5 HZ (300 
beats per minute, bpm) except during ischemia. A saline 
?lled balloon Was inserted in the left ventricle to measure 
developed pressure (DP) and end-diastolic pressure (EDP) 
in mm Hg. After 15 min equilibration, both groups Were 
subjected to 20 min Zero-?oW global ischemia, and then 
Were reperfused for 120 min. 
Left ventricles Were isolated and divided into three seg 
ments along their short axis, stained With triphenyltetraZo 
lium chloride, and stored in formalin. Infarct siZe Was 
measured on digitiZed images and expressed as a percentage 
of myocardium. Data Were expressed as mean plus or minus 
standard error of the mean (:SEM) and Were analyZed using 
a paired Student’s t-Test. Con?dence limits Were established 
at 95%. 
The results are shoWn in FIG. 1, Which is a histogram of 
the infarct siZe in hearts from animals receiving only saline 
(control, solid bar), in animals treated With Deltorphin A 
SEQ ID NO:1 at 2.0 mg/kg (treated, open bar) 24 h prior to 
20 min ischemia and 120 min reperfusion, and animals 
treated With Dermorphin H SEQ ID NO:2 at 2.0 mg/kg 
(treated, hatched bar) 24 h prior to 20 min ischemia and 120 
min reperfusion. Pretreatment of animals With Deltorphin A 
SEQ ID NO:1 or Dermorphin H SEQ ID NO:2 decreased the 
percent of infarct siZe. Control rats had a mean infarct siZe 
of 27:5%, While rats pretreated With Deltorphin A SEQ ID 
NO:1 had a reduced mean infarct siZe of 12.95:3.3%, and 
rats pretreated With Dermorphin H SEQ ID NO:2 had a 
reduced mean infarct siZe of 13.5:3.5%. 
Speci?c infarct volumes in four separate cross sectional 
areas of brains isolated from animals treated post-ischemia 
With DeltorphinASEQ ID NO:1 and Dermorphin H SEQ ID 
NO:2 are shoWn in Tables 1—3. In each case, six male mice 
(strain C57) Were subjected to ischemia for one hour and 
then received an injection of either 100 pl normal saline 
(vehicle), 100 pl of 4.0 mg/kg Deltorphin A SEQ ID NO:1 
(Table 2), or 100 pl of 4.0 mg/kg Dermorphin H SEQ ID 
NO:2 (Table 3). The dose of DeltorphinASEQ ID NO:1 and 
Dermorphin H SEQ ID NO:2 may be in the range of 1 mg/kg 
to 4 mg/kg. Reperfusion folloWed for 24 hours, then animals 
Were sacri?ced and 2 mm brain sections from each of four 
areas Were evaluated. The total cross section area is the sum 
of the four cross section areas; likeWise, the total damaged 
cross section areas is the sum of the four damaged cross 
section areas for each animal. 
TABLE 1 
Saline (Vehicle) Treated 
Cross 14.81 14.65 12.55 13.18 15.35 15.9 
Section 
Area 1 
Cross 22.52 22.39 19.52 20.68 22.08 20.22 
Section 
Area 2 
Cross 25.24 25.45 21.84 23.51 24.77 22.69 
Section 
Area 3 
Cross 24.51 24.05 21.54 24.98 23.81 22.73 
Section 
Area 4 
Total 87.08 86.54 75.45 82.35 86.01 81.54 
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TABLE l-continued TABLE 2-continued 
Saline (Vehicle) Treated Deltorphin A Treated 
Cross 5 Damaged 3.77 3.4 7.36 6.74 6.94 7.11 
Section Cross 
Area Section 
Damaged 6.58 4.49 5.77 5.02 4.83 5.86 Area 4 
Cross 
Section Total 20.1 16.66 29.64 27.28 28.85 27.45 
Area 1 10 Damaged 
Damaged 9.7 6.86 7.42 8.21 8.81 6.57 Cross 
Cross Section 
Section Area 
Area2 Damaged 24.09 19.19 36.72 33.58 34.97 33.71 
Damaged 11.86 10.7 10.65 11.79 9.52 8.24 % 
Cross 15 Corrected 40.2 33.32 59.28 54.56 57.7 54.9 
Section Volume 
Area 3 
Damaged 10.02 12.22 11.03 11.21 10.26 10.76 
Cross For animals receiving Deltorphin A after one hour of 
Sectlon ischemia, the infarct volume Was reduced to about 30% 
Are/a4 20 (total damaged cross section area of 149.98, total cross 
Total 3816 3427 3487 3623 3342 3143 section are of 496.12, 149.98/496.12=0.302). In all siX 
Damaged Deltorphin A treated animals, the corrected volume Was 
Cross 299.96, yielding an infarct volume of 49.99 mm3 (299.96/6), 
Sectlon With a standard deviation of 110,63. 
Area 
Damaged 43.82 39.60 46.22 44.00 38.86 38.55 25 
0/0 TABLE 3 
Corrected 87.644 68.54 69.74 72.46 66.84 62.86 
Volume Dermorphin H Treated 
Cross 14.92 13.87 14.94 14.65 13.69 14.27 
_ _ _ _ 30 Section 
For animals receiving only saline after one hour of Are/a1 
ischemia, the infarct volume Was about 42% (total damaged Cross 2262 21.52 21.48 22.33 21.66 21.36 
cross section area of 208.38, total cross section area of iecnozn 
1163. 
498.97, 208.38/4'98.9'7=0.417). The corrected volume Was Cross 235 238 2369 2398 2371 2235 
obtained by multiplying the damaged cross section area by 35 Section 
2, since 2 mm sections Were assessed. In all siX control Are/a3 
animals this Was 428.08, yielding an average infarct volume gross 23-8 2124 2159 21-87 22-43 2339 
of 71.35 mm3 (428.08/6), With a standard deviation of A2211? 
18,598. 
Total 84.84 80.43 81.7 82.83 81.49 81.37 
TABLE 2 40 Cross 
Section 
. Area 
Deltorphm A Treated Damaged 4.5 5.24 3.76 4.25 3.99 3.47 
Cross 16.42 15 13.89 14.67 15.23 14.56 CYOSF 
Section Secnon 
Area 1 45 Area 1 
Cross 22.07 22.81 20.06 21.23 20.78 21.34 Damaged 5-41 6-75 5-2 7-13 5-87 5-13 
Section CrOS_S 
Area 2 Section 
Cross 24.17 25.51 23.52 23.79 24.14 24.56 Area 2 
Section Damaged 6.43 7.34 4.82 6.77 6.22 5.36 
Area 3 50 cros_s 
Cross 20.77 23.49 23.24 21.55 22.34 20.98 Sectlon 
Section Area 3 
Area 4 Damaged 3.45 3.23 3.37 4.62 4.15 3.89 
Cross 
Total 83.43 86.81 80.71 81.24 82.49 81.44 Sectlon 
Cross 55 Area 4 
Section 
Area Total 19.79 22.56 17.15 22.77 20.23 17.85 
Damaged 5.16 4.14 5.09 4.98 5.32 4.76 Damaged 
Cross Cross 
Section Section 
Area 
Area 1 6O 
Damaged 748 586 7_7 697 736 683 Damaged 23.33 28.05 20.99 27.49 24.83 21.94 
Cross % 
Section Corrected 39.58 45.12 34.3 45.54 40.46 35.7 
Area 2 Volume 
Damaged 3.69 3.26 9.49 8.59 9.23 8.75 
Cross _ _ _ _ 
Section 65 For animals receiving Dermorphln H after one hour of 
Area3 ischemia, the infarct volume Was reduced to about 24% 
(total damaged cross section area of 120.35, total cross 
US 6,900,178 B2 
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section are of 492.66, 120.35/492.66=0.244. In all siX Der 
morphin H treated animals, the corrected volume Was 240.7, 
yielding an infarct volume of 40.12 mm3 (240.7/6), With a 
standard deviation of 4.652. 
These results are summarized as folloWs. 
Average Infarct Standard 
Treatment Volume (mm3) Deviation Infarct Volume 
Control 71.35 8.598 42% 
Deltorphin A 49.99 10.63 30% 
Dermorphin H 40.12 4.652 24% 
The data demonstrate the ef?cacy of Deltorphin A and 
Dermorphin H treatment post cerebral ischemia. 
Pretreatment With Deltorphin A SEQ ID NO:1 and Der 
morphin H SEQ ID NO:2 also signi?cantly decreased the 
cardiac form of troponin I (cTn-1) values following 20 min 
ischemia, as shoWn in FIG. 2. An increase in cTn-1, a protein 
associated speci?cally With the cardiac muscle, indicates 
myocardial damage, likeWise, a decrease in cTn-1 indicates 
less cardiac damage. 
FIG. 3 is a histogram shoWing cTn-I released during 
reperfusion of isolated hearts after 20 min ischemia in rats 
treated 24 h prior to ischemia With 0.5 ml saline (control), 
2.0 mg/kg Deltorphin A SEQ ID NO:1, and 2.0 ml/kg 
Dermorphin H SEQ ID NO:2. The solid bars represent 
control animals (n=6), the open bars represent Deltorphin A 
SEQ ID NO:1 treated animals (n=6), and the hatched bars 
represent Dermorphin H SEQ ID NO:2 treated animals 
(n=6). At time points during reperfusion Where samples Were 
collected for cTn-1 analysis (1, 60, and 120 min 
reperfusion), Tn-1 levels in control rats Were signi?cantly 
higher than Tn-1 levels in Deltorphin A SEQ ID NO:1 
treated rats at 1 min and 60 minutes folloWing reperfusion, 
and Were also higher at 120 min folloWing reperfusion. Tn-1 
levels in control rats Were higher than Tn-1 levels in 
Dermorphin H SEQ ID NO:2 treated rats at 1 minute and 
120 minutes folloWing reperfusion. This data indicated that 
pretreatment With Deltorphin A SEQ ID NO:1 and Dermor 
phin H SEQ ID NO:2 decreased the damage to the 
myocardium, as compared to untreated animals. 
Deltorphin A SEQ ID NO:1 and Dermorphin H SEQ ID 
NO:2 pretreatment also resulted in improved postischemic 
ventricular function. FIG. 3 is a graph of end diastolic 
pressure in mm/Hg in the left ventricle (LVEDP) during 
reperfusion of isolated rat hearts after 20 min ischemia in 
rats pretreated 24 h prior to ischemia With 2.0 mg/kg 
Deltorphin A SEQ ID NO:1 or 2.0 mg/kg Dermorphin H 
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SEQ ID NO:2. Open squares are from treated animals, and 
solid circles are from animals treated With 0.5 ml saline 
(control). FIG. 4 is a graph shoWing percent of functional 
recovery during reperfusion of isolated rat hearts after 20 
min ischemia in rats treated 24 h prior to ischemia With 2.0 
mg/kg DeltorphinASEQ ID NO: 1 or 2.0 mg/kg Dermorphin 
H SEQ ID NO:2. Open squares are from treated animals, and 
solid circles are from control animals. Differences in recov 
ery of developed pressure (DP) in hearts from Deltorphin A 
SEQ ID NO:1 and Dermorphin H SEQ ID NO:2 treated 
animals remained loWer folloWing the initiation of 
reperfusion, as shoWn in FIG. 3. As shoWn in FIG. 4, left 
ventricular functional recovery (% recovery of baseline 
preischemic developed pressure during reperfusion) for ani 
mals treated With 2 mg/kg Deltorphin A SEQ ID NO:1 Was 
signi?cantly increased over control animals up to 120 min 
folloWing reperfusion (p=0.01). Left ventricular functional 
recovery for animals treated With Dermorphin-H SEQ ID 
NO:2 (2.0 mg/kg) Was also increased over control animals 
up to 120 min post reperfusion, but the increase Was not 
statistically signi?cant. 
As shoWn in FIG. 5, left ventricular functional recovery 
Was signi?cantly improved in Deltorphin A SEQ ID NO:1 
treated animals (about 85%) (open bar) compared to control 
animals (about 51%) (solid bar) at 5 min of reperfusion, 
While left ventricular functional recovery in Dermorphin H 
SEQ ID NO:2 treated animals and control animals Was about 
the same (about 51%). 
These results shoW that in a normoXic, isolated perfused 
rat heart preparation, administration of Deltorphin ASEQ ID 
NO:1 and Dermorphin H SEQ ID NO:2 confers cardiopro 
tection When administered either prior to planned ischemia 
or post ischemia. The salutary effects on the post-ischemic 
myocardium include reduced infarct siZe, reduced infarct 
volume, decreased release of cardiospeci?c troponin I, and 
improved ventricular performance. 
As another bene?t, Deltorphin A SEQ ID N011 and 
Dermorphin H SEQ ID NO:2 may provide a bene?t in 
protecting against arrhythmias, similar to the effect of the 
o-opioid receptor agonist TAN -67, as reported by Fryer et al. 
in 274 J. Biol. Chem. 451—457, 2000, Which is expressly 
incorporated by reference herein in its entirety. 
The invention in its broader aspects is therefore not 
limited to the speci?c details, representative apparatus and 
method, and illustrative eXamples shoWn and described. 
Accordingly, departures may be made from such details 
Without departing from the spirit or scope of applicant’s 
general inventive concept. 
SEQUENCE LISTING 
NUMBER OF SEQ ID NOS: 2 
SEQ ID NO 1 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
NAME/KEY: MODQRES 
LOCATION: (1)...(7) 
OTHER INFORMATION: Xaa = 
synthesized 
<400> SEQUENCE: l 
D-Met; artificial sequence is completely 
US 6,900,178 B2 
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-continued 
Tyr Xaa Phe His Leu Met Asp 
l 5 
SEQ ID NO 2 
LENGTH: 13 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
NAME/KEY: MODQRES 
LOCATION: (1)...(13) 
OTHER INFORMATION: Xaa = 
synthesized 
<400> SEQUENCE: 2 
Tyr Xaa Phe Gly Tyr Pro Se]: Gly Glu Ala Lys Lys Ile 
l 5 l0 
D-Ala; artificial sequence is completely 
What is claimed is: 
1. A method of protecting against ischemia and reperfu 
sion injury in a mammal comprising administering a com 
pound selected from the group consisting of Deltorphin A 
SEQ ID NO:1, Dermorphin H SEQ ID N012, and combi 
nations thereof to the mammal in a pharmaceutically accept 
able formulation and an effective amount. 
2. The method of claim 1 Wherein administration is prior 
to onset of ischemia. 
3. The method of claim 2 Wherein administration is about 
24 hours prior to onset of ischemia. 
4. The method of claim 1 Wherein Deltorphin A SEQ ID 
NO:1 and Dermorphin H SEQ ID NO:2 are administered as 
a solution. 
5. The method of claim 1 Wherein Deltorphin A SEQ ID 
NO:1 and Dermorphin H SEQ ID NO:2 are administered 
parenterally. 
6. The method of claim 1 Wherein Deltorphin A SEQ ID 
NO:1 and Dermorphin H SEQ ID NO:2 are administered at 
a concentration of about 2 mg/kg of body Weight of the 
mammal. 
7. The method of claim 1 Wherein Deltorphin A SEQ ID 
NO:1 and Dermorphin H SEQ ID NO:2 are administered to 
protect against myocardial ischemia. 
8. The method of claim 1 Wherein the formulation further 
includes a compound having an anti-ischemic effect. 
9. The method of claim 8 Wherein the compound affects 
nitric oxide synthase. 
10. The method of claim 9 Wherein the compound is 
arginine hydrochloride. 
11. A method to preserve an isolated organ comprising 
exposing the organ to a solution comprising a preservative 
and an effective amount of a compound selected from the 
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group consisting of Deltorphin A SEQ ID NO:1, Dermor 
phin H SEQ ID N012, and combinations thereof. 
12. The method of claim 11 Wherein the organ is selected 
from the group consisting of a heart and a liver. 
13. The method of claim 11 Wherein DeltorphinASEQ ID 
NO:1 is at a concentration of about 100 pM in the solution. 
14. The method of claim 11 Wherein Dermorphin H SEQ 
ID NO:2 is at a concentration of about 100 pm in the 
solution. 
15. A method for reducing effects of ischemia in a 
mammal comprising administering an effective amount of a 
compound selected from the group consisting of Deltorphin 
A SEQ ID NO:1, Dermorphin H SEQ ID NO:2 and com 
binations thereof in a pharmaceutically acceptable carrier to 
the mammal. 
16. The method of claim 15 Wherein said compound is 
administered prior to ischemia. 
17. The method of claim 15 Wherein said compound is 
administered concurrently With onset of ischemia. 
18. The method of claim 15 Wherein said compound is 
administered after one hour of cerebral ischemia. 
19. A method of protecting a mammal against cardiac 
arrhythmias comprising administering a compound selected 
from the group consisting of Deltorphin A SEQ ID NO:1, 
Dermorphin H SEQ ID NO:2 and combinations thereof to 
the mammal in an effective amount and a pharmaceutically 
acceptable formulation. 
20. A solution to preserve viability of an isolated organ 
comprising a compound selected from the group consisting 
of Deltorphin A SEQ ID NO:1, Dermorphin H SEQ ID 
NO:2, and combinations thereof at a concentration effective 
to protect the organ from ischemic injury. 
* * * * * 
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